Compare ADMA Biologics Inc (ADMA) vs Oklo Inc (OKLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Oklo Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Oklo Inc trades at $46.6 (market cap $8.33B). The key difference: Oklo Inc is far larger — about 3.9× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | OKLO | |
|---|---|---|
Market Cap | $2.13B | $8.33B |
Sector | Health | Technology |
52-Week High | $20.38 | $174.14 |
52-Week Low | $7.60 | $45.58 |
Enterprise Value | $2.20B | $6.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
OKLO trades at $51.84, down 0.99% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $105.66 million for 2025 and negative cash flow from operations. Recent positive developments include DOE safety approval for its Groves Isotope Test Reactor and strategic acquisitions to accelerate reactor development.
Analyst consensus remains strongly bullish with a $96 price target, but execution risks and sustained losses pose challenges. The stock's outlook hinges on successful reactor deployment and achieving profitability amid high cash burn. Investors should weigh the high growth potential against substantial operational and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
